Drugs /

vincristine

Back to Drugs List

Overview

Generic Name(s):
vincristine
Trade Name(s):
Vincasar
NCI Definition [1]:
A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)

Clinical Trials

View Clinical Trials for vincristine

Vincristine has been investigated in 143 clinical trials, of which 133 are open and 10 are closed. Of the trials investigating vincristine, 4 are early phase 1 (4 open), 21 are phase 1 (18 open), 19 are phase 1/phase 2 (18 open), 50 are phase 2 (46 open), 4 are phase 2/phase 3 (3 open), 37 are phase 3 (36 open), 5 are phase 4 (5 open), and 3 are no phase specified (3 open).

MS4A1 Expression, BCR-ABL1 Fusion, and t(9;22)(q34;q11) are the most frequent biomarker inclusion criteria for vincristine clinical trials.

Diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and B-cell acute lymphoblastic leukemia are the most common diseases being investigated in vincristine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vincristine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vincristine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vincristine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
vincristine [chemical/ingredient], vincristine, leurocristine, vincrystine, leurocristine, 22-oxovincaleukoblastine, vincristine (substance), vincristinum, oxovincaleukoblastine, vincristine, vincristine, vincristin, vincristina, vincaleukoblastine, 22-oxo-, 22-oxovincaleukoblastin, 57-22-7, vincristine (product), lcr, leurocristine, 22-oxovincaleukoblastine, Vincasar, vcr
Drug Categories [2]:
Antimicrotubule agents
NCIT ID [1]:
C933
SNOMED ID [1]:
F-61C99

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.